| Not Yet Recruiting | Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer Pancreatic Cancer | Phase 2 | 2026-12-01 |
| Not Yet Recruiting | ctDNA-Guided Chemotherapy Omission With Ribociclib Plus Endocrine Therapy in HR-Positive/HER2-Negative Breast Breast Cancer | Phase 2 | 2026-10-01 |
| Not Yet Recruiting | Neoadjuvant Imlunestrant Plus Abemaciclib Treatment Guided by Ki67 Index After 2 Weeks for ER-Positive HER2-Ne Breast Cancer | Phase 2 | 2026-07-01 |
| Not Yet Recruiting | Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal C RAS Wild Type mCRC | Phase 2 | 2026-06-01 |
| Not Yet Recruiting | Neoadjuvant Moderately Hypofractionated Radiotherapy Combined With Chemotherapy and Immunotherapy for High-ris Rectal Cancer, Moderately Hypofractionated Radiotherapy, Serplulimab | Phase 2 | 2026-06-01 |
| Not Yet Recruiting | Rezvilutamide With Radical Prostatectomy and Metastasis-Directed Therapy in Oligometastatic Prostate Cancer Oligometastatic Prostate Cancer | Phase 2 | 2026-05-01 |
| Not Yet Recruiting | Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy Breast Cancer | Phase 3 | 2026-05-01 |
| Not Yet Recruiting | A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Canc Penile Cancer | Phase 2 | 2026-05-01 |
| Suspended | Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC Esophageal Squamous Cell Carcinoma | Phase 2 | 2026-04-20 |
| Not Yet Recruiting | Tpex Subsets in Negative Tumor Draining Lymph Nodes for Predicting the Efficacy of PD 1 Inhibitors in Advanced Esophageal Cancer | — | 2026-04-20 |
| Not Yet Recruiting | Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma Hepato Cellular Carcinoma (HCC) | Phase 2 | 2026-04-15 |
| Not Yet Recruiting | QLC5513 Alone or in Combination With QL1706 in Previously Treated Advanced or Metastatic TNBC. Triple-negative Breast Cancer (TNBC) | Phase 2 | 2026-04-15 |
| Not Yet Recruiting | Anlotinib and Benmelstobart in DTC Thyroid Cancer | Phase 2 | 2026-04-01 |
| Not Yet Recruiting | Efficacy of Sintilimab Combined With Bevacizumab and XELOX/SOX in Initially Unresectable AFP-positive Gastric/ Gastric Cancer (GC), AFP Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2026-04-01 |
| Not Yet Recruiting | Umbrella Trial of Neoadjuvant Therapy for Locally Advanced Colorectal Cancer Locally Advanced Colorectal Cancer | Phase 2 | 2026-04-01 |
| Not Yet Recruiting | Iparomlimab Plus Tovorilimab Combined With Bevacizumab and Chemotherapy as First-Line Treatment for Advanced M Mesothelioma | Phase 2 | 2026-04-01 |
| Not Yet Recruiting | Air Purifier Use and Respiratory Health in COPD Patients Respiratory Health | N/A | 2026-04-01 |
| Not Yet Recruiting | Dynamic ctDNA-Guided Adjuvant Therapy in cStage III and IVA Gastric or Gastroesophageal Junction Adenocarcinom ctDNA, Gastric Cancer, Gastroesophageal Junction (GEJ) Adenocarcinoma | Phase 2 | 2026-04-01 |
| Not Yet Recruiting | Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Prima Breast Cancer | Phase 2 | 2026-03-31 |
| Not Yet Recruiting | CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（ Breast Cancer | Phase 3 | 2026-03-31 |
| Not Yet Recruiting | Eradication of Helicobacter Pylori Subtypes at High Gastric Cancer Risk: a Cluster-randomized Controlled Trial Gastric (Stomach) Cancer | N/A | 2026-03-30 |
| Recruiting | Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma Maintenance Treatment of Peripheral T-cell Lymphoma | Phase 3 | 2026-03-27 |
| Not Yet Recruiting | Mesh Infection After Hernioplasty: Complete vs Partial Removal - Retrospective Study on Outcomes and Pathogen Inguinal Hernia Repair, Mesh Infection | — | 2026-03-18 |
| Not Yet Recruiting | Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Th Liver Cancer (Primary and Metastatic), Liver Ablation | N/A | 2026-03-16 |
| Not Yet Recruiting | Study of Multi-mode Thermal Therapy Combined With Immunotherapy In Patients With HER2-negative Breast Cancer W HER2-negative Breast Cancer | Phase 2 | 2026-03-15 |
| Recruiting | Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breas Metastatic Breast Cancer ( HER2 Negative) | Phase 2 | 2026-03-11 |
| Not Yet Recruiting | Study of MRI Guided Personal Chemoradiotherapy and Immunotherapy for Limited Advanced Esophageal Squamous Caic Advanced Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma | Phase 2 | 2026-03-10 |
| Recruiting | SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPC Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer) | Phase 2 | 2026-03-02 |
| Not Yet Recruiting | Eribulin Mesylate-based Therapy in Patients With Advanced HER2-negative Breast Cancer Previously Treated With Treatment Efficacy | — | 2026-03-01 |
| Enrolling By Invitation | Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer Liver Metastases From Colorectal Cancer (mCRC) | Phase 2 | 2026-03-01 |
| Not Yet Recruiting | Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC HCC - Hepatocellular Carcinoma | Phase 2 | 2026-03-01 |
| Not Yet Recruiting | A Platform Study Based on Specific Tracer for Evaluating the Therapeutic Efficacy of Systemic Treatment for Br Breast Cancer | Phase 2 | 2026-03-01 |
| Not Yet Recruiting | Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Breast Cancer | Phase 3 | 2026-02-26 |
| Recruiting | Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLC Resectable Stage II-IIIa Squamous NSCLC | Phase 2 | 2026-02-05 |
| Not Yet Recruiting | A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC Non-small Cell Lung Cancer, RET Fusion, Pralsetinib | N/A | 2026-02-05 |
| Not Yet Recruiting | Iparomlimab and Tuvoraleimab Injection in Combination With Bevacizumab, Albumin-bound Paclitaxel, and Carbopla Acral Melanoma, Mucosal Melanoma | Phase 2 | 2026-02-01 |
| Not Yet Recruiting | Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer Colorectal Cancer (MSI-H) | Phase 2 | 2026-02-01 |
| Not Yet Recruiting | Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer SCLC, Extensive Stage, Toripalimab | — | 2026-02-01 |
| Not Yet Recruiting | Adjuvant Intensification for LAR Breast Cancer Females, Triple Negative Breast Cancer (TNBC) | Phase 3 | 2026-02-01 |
| Not Yet Recruiting | FANLUNG-2：The Value of High-Low Mixed-Dose Radiotherapy Combined With Chemo-Immunotherapy Induction in Locally NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 2 | 2026-02-01 |
| Not Yet Recruiting | Fruquintinib Versus Bevacizumab Plus Chemotherapy in Second-Line RAS-Mutant Metastatic Colorectal Cancer (FRU- Colorectal Cancer | Phase 3 | 2026-01-31 |
| Not Yet Recruiting | An Observational Study on Gastric Cancer in High-risk Individuals Gastric Adenocarcinoma | — | 2026-01-31 |
| Not Yet Recruiting | Integrated Clinical-molecular Risk Stratification to Early Recurrence in Colorectal Liver Metastases Colorectal Liver Metastases | — | 2026-01-31 |
| Not Yet Recruiting | Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Triple -Negative Breast Cancer | Phase 2 | 2026-01-30 |
| Recruiting | A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/G Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2026-01-29 |
| Recruiting | RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma Melanoma Advanced | Phase 4 | 2026-01-28 |
| Not Yet Recruiting | Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlot Proteinuria | Phase 4 | 2026-01-28 |
| Recruiting | Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification Endometrial Cancer, Fertility | Phase 2 / Phase 3 | 2026-01-25 |
| Not Yet Recruiting | A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma Hepato Cellular Carcinoma (HCC) | Phase 2 | 2026-01-25 |
| Not Yet Recruiting | Sequencing SG vs. T-DXd in HER2-Low/TROP2-High Metastatic Breast Cancer Metastatic Breast Cancer | Phase 2 | 2026-01-16 |
| Not Yet Recruiting | RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure HER2-positive Breast Cancer, Metastatic Breast Cancer | Phase 2 / Phase 3 | 2026-01-16 |
| Not Yet Recruiting | Huaier Granule and Proteinuria Proteinuria, Breast Cancer Patients | Phase 2 | 2026-01-15 |
| Not Yet Recruiting | Evaluating the Predictive Capability of Transcriptomic Profiling for Identifying the Primary Site of Metastati Malignant Tumor With Metastasis, CUP | — | 2026-01-15 |
| Not Yet Recruiting | Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 2 | 2026-01-09 |
| Recruiting | Comparative Study on the Short- and Long-term Efficacy of Q-ISR, Traditional Sub-ISR, and t-ISR Colorectal Cancer | Phase 2 | 2026-01-07 |
| Not Yet Recruiting | Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes Pancreatic Cancer | Phase 3 | 2026-01-01 |
| Recruiting | Dynamic Circulating Tumor DNA Monitoring to Guide Systemic Therapy in Gastric Cancer Gastric Cancer | Phase 2 | 2026-01-01 |
| Recruiting | G-CSF Combined With IL-11 on Hematopoietic Reconstitution After Autologous Hematopoietic Stem Cell Transplanta Mobilization of Hematopoietic Stem Cells (HSC) to Peripheral Blood (PB), Hematopoetic Stem Cell Transplantation, Hemato-oncologic Patients | Phase 2 | 2026-01-01 |
| Not Yet Recruiting | A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatm Rhabdomyosarcoma | Phase 2 | 2026-01-01 |
| Recruiting | Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBC Breast Cancer Female NOS, General Anxiety Disorder, Depressive Disorder | — | 2026-01-01 |
| Recruiting | Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders Epstein-Barr Virus-associated Lymphoproliferative Diseases, Chronic Active Epstein-Barr Virus Infection, EBV Associated Lymphoma | Phase 2 | 2026-01-01 |
| Not Yet Recruiting | AI for Renal Tumors Using Non-Contrast CT Renal Neoplasms, Renal Cyst | — | 2026-01-01 |
| Not Yet Recruiting | A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 I Breast Cancer | Phase 2 | 2025-12-31 |
| Not Yet Recruiting | Chinese Herbal Therapy (Qiqi Shengmai Formula) for Moyamoya Vasculopathy: The CHIMES Trial Moyamoya Disease, Moyamoya Syndrome | Phase 1 | 2025-12-30 |
| Recruiting | ctDNA-guided Treatment Decision-making Metastatic Breast Cancer ( HER2 Negative), ctDNA | Phase 2 | 2025-12-24 |
| Not Yet Recruiting | TITAN-HCC: Neoadjuvant and Adjuvant QL1706 With TACE in Resectable Hepatocellular Carcinoma Beyond Milan Crite Hepatocellular Carcinoma (HCC) | N/A | 2025-12-20 |
| Not Yet Recruiting | Evaluating the Clinical Value of Transparent Cap-Assisted Second Examination of the Sigmoid Colon for Improvin Colorectal Adenoma | N/A | 2025-12-15 |
| Not Yet Recruiting | Impact of Discontinuing GLP-1 Receptor Agonists for Two Weeks Prior to Upper Endoscopy on the Risk of Gastric Gastric Retention | — | 2025-12-10 |
| Not Yet Recruiting | AI-assisted Integrated Care to Promote Colonoscopy Uptake Colorectal Neoplasms, Colonoscopy | N/A | 2025-12-08 |
| Not Yet Recruiting | DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC Bladder (Urothelial, Transitional Cell) Cancer, NMIBC | Phase 3 | 2025-12-01 |
| Not Yet Recruiting | Fecal DNA Methylation and Helicobacter Pylori Gastric Cancer Susceptibility Genes Test Gastric (Stomach) Cancer | — | 2025-12-01 |
| Not Yet Recruiting | Adjuvant Chemotherapy for BTC Based on 3D-PTA Cholangiocarcinoma | Phase 2 | 2025-12-01 |
| Not Yet Recruiting | A Clinical Trial of Envafolimab Combined With Lenvatinib for Kidney Cancer With Liver Spread Clear Cell Renal Cell Cancer (ccRCC), Liver Metastasis | Phase 2 | 2025-12-01 |
| Not Yet Recruiting | CONVERT-HB1: Radical Prostatectomy After Systemic Therapy for High-volume Metastatic Hormone-sensitive Prostat Metastatic Prostate Cancer, Prostate Cancer (Adenocarcinoma), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Phase 2 | 2025-11-30 |
| Completed | Probiotics in Alleviating Microplastic-Induced Obesity Intestinal Functional Disorder, Inflammation | N/A | 2025-11-30 |
| Recruiting | Real-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study Peripheral T-Cell Lymphoma | — | 2025-11-15 |
| Recruiting | A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors Triple Negative Breast Cancer Metastatic, Melanoma Metastatic, Colorectal Cancer Metastatic | Phase 2 | 2025-11-04 |
| Not Yet Recruiting | Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or NSCLC (Non-small Cell Lung Cancer) | Phase 2 | 2025-11-01 |
| Recruiting | Effect of OFA, OSA Versus Opioid-based Anesthesia on NETs and Cancer Cell Malignancy After Colorectal Cancer S Colorectal Cancer, Opioid-free Anesthesia, NETs | N/A | 2025-11-01 |
| Not Yet Recruiting | T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis Breast Cancer With Brain Metastasis, HER2-positive Breast Cancer | Phase 2 | 2025-11-01 |
| Recruiting | Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases Breast Cancer, Radiotherapy | N/A | 2025-10-24 |
| Active Not Recruiting | Predictive Value of Exosomes in Pleural Effusion for Advanced Lung Cancer NSCLC (Advanced Non-small Cell Lung Cancer) | — | 2025-10-16 |
| Not Yet Recruiting | Iparomlimab and Tuvonralimab Combined With GC in Advanced ICC Advanced Intrahepatic Cholangiocarcinoma | Phase 2 | 2025-10-15 |
| Not Yet Recruiting | Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advance Advanced Ovarian Cancer | Phase 2 | 2025-10-10 |
| Recruiting | Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET) Metastatic Colorectal Cancer ctDNA Surveillance | — | 2025-10-10 |
| Recruiting | The Fever Clinic Acute Respiratory Cohort Acute Respiratory Infections, Febrile Illnesses, Community-acquired Pneumonia | — | 2025-10-10 |
| Enrolling By Invitation | The Effects of a Nurse-led TGA-based Pre-rehabilitation Planning on Perioperative Outcomes in Patients With Li Liver Cancer | N/A | 2025-10-08 |
| Not Yet Recruiting | CDK4/6 Inhibitor Intensification and Chemotherapy De-Escalation for Early-stage Luminal-HER2 Breast Cancer Breast Cancer | Phase 3 | 2025-10-07 |
| Not Yet Recruiting | Development and Validation of an Artificial Intelligence-assisted System for Bowel Cleanliness Assessment Base Colorectal Adenoma | — | 2025-10-01 |
| Not Yet Recruiting | A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlot Soft Tissue Sarcoma (STS) | Phase 2 | 2025-10-01 |
| Recruiting | SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatment HER2-positive, Unresectable, Locally Advanced or Metastatic Breast Cancer, SKB264, Inetetamab | Phase 2 | 2025-09-30 |
| Not Yet Recruiting | Vebreltinib for Neoadjuvant in METex 14 Skipping Mutant Stage IIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC) NSCLC, Neoadjuvant Therapy | Phase 2 | 2025-09-30 |
| Not Yet Recruiting | Evaluation of a Vaccine Chatbot on HPV Vaccine Confidence and Hesitancy HPV Vaccine | N/A | 2025-09-26 |
| Recruiting | An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression Breast Cancer | Phase 2 | 2025-09-25 |
| Recruiting | Population Pharmacokinetics of Remifentanil in Low-Weight Critically Ill Patients Critical Illness, Pain | — | 2025-09-22 |
| Not Yet Recruiting | Impact of a One-Week Discontinuation of Semaglutide on Gastric Retention and Endoscopic Mucosal Visibility Sco Gastric Retention | — | 2025-09-15 |
| Not Yet Recruiting | Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Res Platinum Resistant Ovarian Cancer, Platinum Refractory Epithelial Ovarian Cancer, Ovarian Cancer (OvCa) | Phase 2 | 2025-09-15 |
| Not Yet Recruiting | Impact of Neuropathy on the Risk of Semaglutide-Induced Gastric Retention Gastric Retention | — | 2025-09-15 |
| Not Yet Recruiting | Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II St HER2-positive Breast Cancer | Phase 2 | 2025-09-10 |
| Not Yet Recruiting | The Safety, Efficacy, and Immune Response of Multimodal Thermal Therapy in the Treatment of Malignant Liver Tu Hepatocellular Carcinoma, Colorectal Cancer Liver Metastasis | N/A | 2025-09-10 |
| Recruiting | Conversion Therapy With RC48, Sintilimab, and SOX for HER2 1+/2+ Unresectable Gastric Cancer Gastric Cancer | Phase 2 | 2025-09-04 |
| Not Yet Recruiting | De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Phase 3 | 2025-09-01 |
| Not Yet Recruiting | Yueju Pill Combined With Standard Therapy In Advanced Biliary Tract Cancer Biliary Tract Cancer (BTC) | N/A | 2025-09-01 |
| Not Yet Recruiting | T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis Breast Cancer With Brain Metastasis, HER2-low Expressing Breast Cancer | Phase 2 | 2025-09-01 |
| Recruiting | Multicentric Database for Solid Pseudopapillary Neoplasm of the Pancreas Solid Pseudopapillary Neoplasm of the Pancreas | — | 2025-09-01 |
| Not Yet Recruiting | Multimodal Large Model-Driven Risk and Prognosis Assessment for Brain Metastases in Lung Cancer AI (Artificial Intelligence), NSCLC Brain Metastasis | — | 2025-09-01 |
| Not Yet Recruiting | Cryoablation Combined With SHR-1701 Plus Famitinib in Patients With Advanced Intrahepatic Cholangiocarcinoma. Advanced Intrahepatic Cholangiocarcinoma | Phase 2 | 2025-09-01 |
| Not Yet Recruiting | Low-Dose Radiotherapy in Patients With Advanced Esophageal Squamous Cell Carcinoma Resistant to First-Line Che Esophageal Adenocarcinoma, Radiotherapy | Phase 2 | 2025-09-01 |
| Not Yet Recruiting | Randomized Controlled Clinical Study on the Reduction of Tumor Marker Levels in Breast Cancer Patients by Huai Breast Cancer | Phase 4 | 2025-09-01 |
| Recruiting | The Efficacy and Safety of Metformin Intervention in Elderly Overweight or Obesity With Mild Cognitive Impairm Mild Cognitive Impairment, Overweight or Obesity, Elderly | Phase 1 / Phase 2 | 2025-09-01 |
| Not Yet Recruiting | Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Advanced Hepatocellular Carcinoma (HCC) | — | 2025-09-01 |
| Recruiting | Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC Nasopharyngeal Carcinoma (NPC) | Phase 3 | 2025-09-01 |
| Completed | Risk of Metachronous Advanced Colorectal Neoplastic Among Individuals With Varying Numbers of Non-Advanced Ade Colorectal Adenoma | — | 2025-09-01 |
| Recruiting | Albumin-bound Paclitaxel-based Second-line Treatment Regimens for Locally Advanced or Metastatic G/GEJ Adenoca Gastric Cancer, Second-line Treatment | — | 2025-09-01 |
| Recruiting | Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibi Locally Advanced Rectal Cancer, Neoadjuvant Therapy | Phase 2 | 2025-08-28 |
| Recruiting | Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahe Intrahepatic Cholangiocarcinoma (Icc) | Phase 2 | 2025-08-20 |
| Recruiting | TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy an Hepatocellular Carcinoma | — | 2025-08-15 |
| Not Yet Recruiting | Intraoperative Margin Techniques for Esophagogastric Junction Adenocarcinoma: A Controlled Study Adenocarcinoma of the Esophagogastric Junction | N/A | 2025-08-15 |
| Recruiting | HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA Mixed Hepatocellular-cholangiocarcinoma | Phase 2 | 2025-08-15 |
| Recruiting | Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Tre Hepatocellular Carcinoma (HCC) | Phase 2 | 2025-08-14 |
| Not Yet Recruiting | EIT Evaluation of Pulmonary Ventilation With Different Ropivacaine Concentrations in Intercostal Nerve Blockad Intercostal Nerve Block, Pulmonary Ventilation, Anesthesia, Local | N/A | 2025-08-10 |
| Recruiting | Zhongshan Ketogenic Diet Study 1 Platelet Function and Thrombus Formation | N/A | 2025-08-10 |
| Not Yet Recruiting | Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced C Colorectal Carcinoma | Phase 1 / Phase 2 | 2025-08-01 |
| Not Yet Recruiting | Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low R Rectal Cancer | Phase 3 | 2025-08-01 |
| Not Yet Recruiting | Transparent Cap-Assisted Colonoscopy Combined With Computer-Aided Detection in Improving the Detection Rate of Colorectal Adenoma | N/A | 2025-08-01 |
| Not Yet Recruiting | MRD-Guided Surveillance in Locally Advanced Mid-Low Rectal Cancer (SURVEILLANCE-III) Colorectal Cancer (CRC) | — | 2025-08-01 |
| Recruiting | A Study of Disitamab Vedotin + Bicalutamide in HER2/AR-Positive Scrotal Paget's Disease Extramammary Paget Disease, Scrotum Disease | Phase 2 | 2025-08-01 |
| Recruiting | Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer Colorectal Cancer | Phase 2 | 2025-08-01 |
| Not Yet Recruiting | A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver Cancer Unresectable Hepatocellular Carcinoma | — | 2025-08-01 |
| Not Yet Recruiting | Risk and Prognosis of Brain Metastasis in Non-Small Cell Lung Cancer NSCLC (Non-small Cell Lung Cancer), Brain Metastases From Non-small Cell Lung Cancer (NSCLC) | — | 2025-08-01 |
| Not Yet Recruiting | MRD-Guided Surveillance in Resectable Stage IV Metastatic Colorectal Cancer (SURVEILLANCE-II) Colorectal Cancer (CRC), Colorectal Cancer Liver Metastases (CRLM) | — | 2025-08-01 |
| Completed | A Prognostic Model for COPD Complicated With Sarcopenic Obesity Based on Bioelectrical Impedance Phase Angle T Sarcopenic Obesity, COPD | — | 2025-08-01 |
| Not Yet Recruiting | MRD-Guided Surveillance in Operable Colon Adenocarcinoma (I-III)(SURVEILLANCE-I) Colorectal Cancer (CRC) | — | 2025-08-01 |
| Recruiting | Incidence of 107 Lymph Node Metastasis Esophageal Cancer | — | 2025-07-21 |
| Recruiting | Incidence of 106TBL Lymph Node Metastasis Esophageal Cancer | — | 2025-07-21 |
| Recruiting | A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined Wi HER2-positive Breast Cancer | Phase 3 | 2025-07-08 |
| Recruiting | Lenvatinib Plus Tislelizumab Versus Lenvatinib Alone in Hepatocellular Carcinoma Previously Treated With Anti- Hepatocellular Carcinoma (HCC) | Phase 2 | 2025-07-02 |
| Recruiting | Prospective Gastric Cancer Screening Using Helicobacter Pylori High-Risk Single Nucleotide Polymorphism Detect Gastric Adenocarcinoma, Helicobacter Pylori | — | 2025-07-01 |
| Recruiting | Prospective Gastric Cancer Screening With Fecal Multi-target DNA Analysis Gastric (Stomach) Cancer | — | 2025-07-01 |
| Not Yet Recruiting | Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients Colon Cancer | Phase 2 | 2025-07-01 |
| Recruiting | An Observational Study for Gastric Cancer in Carriers of High Risk Helicobacter Pylori Gastric (Stomach) Cancer, Helicobacter Infection | — | 2025-07-01 |
| Not Yet Recruiting | An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer Colorectal Cancer Metastatic | Phase 2 | 2025-07-01 |
| Not Yet Recruiting | Phase II Study of Utidelone Plus Fruquintinib Combination Therapy for Platinum-Resistant Recurrent Ovarian Can Platinum Resistant Ovarian Cancer | Phase 2 | 2025-07-01 |
| Not Yet Recruiting | Study of SHR-A2102 Combined Other Antitumor Drugs in Advanced Breast Cancer Advanced Breast Cancer | Phase 2 | 2025-06-30 |
| Not Yet Recruiting | Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC Patients Breast Cancer, TNBC | Phase 3 | 2025-06-16 |
| Recruiting | CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cance Breast Cancer, Adjuvant Therapy | Phase 3 | 2025-06-15 |
| Not Yet Recruiting | Chemo-free in Older (≥65) Node-Positive ER+/HER2- Breast Cancer Breast Cancer, Adjuvant Therapy | Phase 3 | 2025-06-15 |
| Recruiting | Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer Esophageal Neoplasms | N/A | 2025-06-05 |
| Not Yet Recruiting | Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Ad Breast Cancer | Phase 3 | 2025-06-02 |
| Not Yet Recruiting | Exosome-based Recurrence Score for Post-Treatment Ovarian Cancer Ovarian Cancer | — | 2025-06-01 |
| Not Yet Recruiting | UEMR Versus HSP in the Treatment of Pedunculated Colorectal Polyps Less Than 10mm in Size Pedunculated Colorectal Polyp | N/A | 2025-06-01 |
| Not Yet Recruiting | TACE Plus Ivonescimab for Unresectable Non-Metastatic HCC Hepatocellular Carcinoma (HCC) | Phase 1 | 2025-06-01 |
| Not Yet Recruiting | Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer TNBC, Triple Negative Breast Cancer | Phase 2 | 2025-06-01 |
| Recruiting | HPV Genotype Attribution and Disease Burden of Anal Cancer in China Anal Cancer | — | 2025-06-01 |
| Not Yet Recruiting | Preservation Vs. Dissection of No. 253 Lymph Nodes of Robotic Resection for Mid/Low Rectal Cancer Rectal Cancer | N/A | 2025-06-01 |
| Not Yet Recruiting | Patient Education Strategy for Breast Cancer Patients During Perioperative Hospitalization Stage Breast Carcinoma, Patient Education, Perioperative Care | N/A | 2025-06-01 |
| Recruiting | Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC Colo-rectal Cancer, MSIhi or dMMR Advanced Unresectable or Metastatic Solid Tumors, Including Colorectal Cancers | Phase 2 | 2025-06-01 |
| Not Yet Recruiting | The Effect of Cap-assisted Water Exchange Colonoscopy on Straight Passage of the Colonoscope Through the Sigmo Colonoscope Passage | N/A | 2025-06-01 |
| Recruiting | Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation, Advanced PDTC or ATC With NRAS Mutation | Phase 2 | 2025-05-27 |
| Recruiting | A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidociti Natural Killer/T-cell Lymphoma, Relapsed or Refractory Lymphoma Including ENKL | Phase 1 / Phase 2 | 2025-05-26 |
| Recruiting | GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment （BTC-I Advanced Biliary Tract Cancer | — | 2025-05-23 |
| Recruiting | A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | 2025-05-13 |
| Recruiting | Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patient Diffuse Large B-Cell Lymphoma, DLBCL | — | 2025-05-09 |
| Recruiting | Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxalipl Diffuse Large B-Cell Lymphoma | Phase 2 | 2025-05-08 |
| Not Yet Recruiting | Active Surveillance for Limited GGNs Lung Ground-glass Opacities, Active Surveillance | — | 2025-05-01 |
| Active Not Recruiting | Understanding the Public Impact on Dengue Vaccination Strategies in Yunnan Province, China: A Dynamic Transmis Dengue Vaccination Strategy Evaluation, Transmission Modeling of Dengue, Public Health Impact of Vaccination | — | 2025-05-01 |
| Not Yet Recruiting | Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (BTC) | Phase 2 | 2025-05-01 |
| Not Yet Recruiting | Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Adv Laryngeal Carcinoma, Hypopharyngeal Carcinoma | Phase 3 | 2025-04-28 |
| Completed | Ozone Reaction Products and Skin Health Skin Health | N/A | 2025-04-28 |
| Recruiting | Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomainten Limited Stage Small Cell Lung Cancer | Phase 2 | 2025-04-25 |
| Recruiting | Effect of Surgical Margin Width on Recurrence and Survival in Patients With Hepatic Oligometastasis of Colorec Oncology, Tumor Recurrence and Metastasis | N/A | 2025-04-21 |
| Recruiting | TQB2450 Plus Progestin for Fertility-sparing Treatment in MMRd EC Endometrial Cancer | Phase 2 | 2025-04-21 |
| Recruiting | RGL-305+ Lymphoma + Exploratory Clinical Study Lymphoma Patients With Complete Response (CR) or Partial Response (PR) After Standard Treatment Had a Positive Minimal Residual Lesion (MRD) | N/A | 2025-04-21 |
| Enrolling By Invitation | Breast Cancer PET/CT Imaging With 68Ga-pAKTi Breast Cancers, PIK3CA Mutation-Related Tumors, PI3K Pathway Activated Tumors | — | 2025-04-21 |
| Recruiting | MRG003 and Pucotenlimab to Treat Locally Advanced or Metastatic ATC/PDTC Thyroid Cancer | Phase 2 | 2025-04-21 |
| Recruiting | Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain Metast Breast Cancer | Phase 1 / Phase 2 | 2025-04-18 |
| Not Yet Recruiting | Study on the Safety and Efficacy of Intratumoral Administration of IDOV-SAFETM in the Treatment of Advanced So Advanced Malignant Solid Tumor | EARLY_Phase 1 | 2025-04-10 |
| Recruiting | Neoadjuvant SNF Precision Therapy Phase III Neoadjuvant Therapy | Phase 3 | 2025-04-08 |
| Not Yet Recruiting | HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer Advanced Triple Negative Breast Cancer | Phase 2 | 2025-04-01 |
| Not Yet Recruiting | Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic G Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Peritoneal Metastasis | Phase 2 | 2025-03-30 |
| Completed | Lung Atelectasis Improvement Through Positive End Expiratory Pressure During Anesthetic Induction Lung Injury, Acute | N/A | 2025-03-28 |
| Recruiting | Tamoxifen for Advanced Solid Pseudopapillary Tumor of the Pancreas Pancreatic Neoplasms | Phase 2 | 2025-03-20 |
| Recruiting | Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahe Intrahepatic Cholangiocellular Carcinoma | Phase 2 | 2025-03-18 |
| Recruiting | HAIC Combined with Sintilimab Plus Bevacizumab Biosimilar for Advanced Hepatocellular Carcinoma (TASK-03) Hepatocellular Carcinoma (HCC) | Phase 2 | 2025-03-18 |
| Recruiting | Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Locally Recurrent Rectal Cancer | Phase 2 | 2025-03-10 |
| Recruiting | Hypofractionated Radiotherapy Combined With NALIRIF, PD-1 Antibody in Locally Recurrent Rectal Cancer(NOVELTY- Locally Recurrent Rectal Cancer | Phase 2 | 2025-03-09 |
| Recruiting | Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin Reactions Breast Cancer | Phase 3 | 2025-03-07 |
| Not Yet Recruiting | Predicting Gastric Neoplasia in Patients with High-risk Endoscopic Features Gastric Neoplasia | — | 2025-03-01 |
| Recruiting | Perioperative Immunotherapy for Resectable Limited-Stage SCLC Perioperative Immunotherapy, Limited Stage Lung Small Cell Carcinoma, Resectable Small Cell Lung Cancer | Phase 2 | 2025-03-01 |
| Recruiting | Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanc Advanced Colorectal Carcinoma, Immunotherapy | Phase 2 | 2025-03-01 |
| Recruiting | Second-line Standard Treatment Sequential TAS-102 and Bevacizumab Combined With Local Treatment in Advanced Co Metastatic Colorectal Cancer (CRC) | Phase 2 | 2025-02-28 |
| Recruiting | A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Adva Advanced HR - Positive, HER2 - Negative Breast Cancer, Resistant to (Neo)Adjuvant Endocrine Therapy | N/A | 2025-02-28 |
| Recruiting | Irinotecan Liposomes Combined with Cetuximab + Vermofenib in First-line Failure of Advanced Colorectal Cancer Colorectal Cancer Metastatic | Phase 2 | 2025-02-26 |
| Recruiting | IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) Soft Tissue Sarcomas, Angiosarcoma, Fibrosarcoma | Phase 2 | 2025-02-25 |
| Recruiting | POLA-R-CHP in the First-line Treatment of Transformed DLBCL Transformed Lymphoma | Phase 2 | 2025-02-17 |
| Recruiting | The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the NSCLC, Stereotactic Body Radiation Therapy (SBRT), Immunotherapy | Phase 2 | 2025-02-15 |
| Enrolling By Invitation | AI-LLM Communication Aid in Prostate Cancer Care (AI-CAP） Prostate Cancer | N/A | 2025-02-15 |
| Not Yet Recruiting | Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Canc TNBC - Triple-Negative Breast Cancer | — | 2025-02-15 |
| Not Yet Recruiting | Heterogeneity of 68Ga-FAPI Uptake As Imaging Biomarker in T-DXd Treatment for Brain Metastasis of HER2 Positiv Breast Cancer, Metastatic Breast Cancer | Phase 2 | 2025-02-15 |
| Recruiting | Reverse HER2-negative Immune Resistant Breast Cancer HER2 Negative Breast Cancer | Phase 2 | 2025-02-12 |
| Not Yet Recruiting | Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC | Phase 2 | 2025-02-10 |
| Recruiting | Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon Mutations Non Small Cell Lung Cancer | Phase 2 | 2025-02-07 |
| Recruiting | CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC Esophageal Carcinoma, Radiotherapy, Immunotherapy | Phase 3 | 2025-02-01 |
| Not Yet Recruiting | Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients Triple-negative Breast Cancer | Phase 3 | 2025-02-01 |
| Recruiting | ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer | Phase 2 | 2025-01-15 |
| Not Yet Recruiting | Capecitabine in Low Risk Triple Negative Breast Cancer Breast Cancer | Phase 2 | 2025-01-15 |
| Recruiting | Study on the Mechanism of Acquired Resistance of Entrectinib ROS1 Fusion Positive, Non Small Cell Lung Cancer | — | 2025-01-15 |
| Recruiting | Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis Breast Cancer Metastatic, Breast Cancer Brain Metastases | Phase 1 / Phase 2 | 2025-01-08 |
| Recruiting | AI-Enhanced Imaging in Population Breast Cancer Screening Breast Cancer Screening | N/A | 2025-01-01 |
| Recruiting | Perioperative Toripalimab and Endostatin for Stage II Melanoma: A Phase II Trial Melanoma of Skin, Acral Melanoma, Stage II Melanoma | Phase 2 | 2025-01-01 |
| Recruiting | HAIC Combined with Donafenib and Sintilimab As Perioperative Treatment for Resectable Hepatocellular Carcinoma Hepato Cellular Carcinoma (HCC) | Phase 2 | 2025-01-01 |
| Active Not Recruiting | Fecal DNA Methylation and Helicobacter Pylori SNPs Tests for Gastric Cancer Gastric (Stomach) Cancer | — | 2025-01-01 |
| Not Yet Recruiting | Study of HRS-2189 Combined HRS-5041 in Prostate Cancer Prostate Cancer Metastatic Disease | Phase 2 | 2024-12-31 |
| Active Not Recruiting | Comparison Between ER Loss and Triple-Negative Breast Cancer Guided by 18F-FES PET/CT in Metastatic Breast Can Breast Cancer | — | 2024-12-31 |
| Recruiting | Precision Palliative Care for Patients With Advanced Esophageal Cancer Esophageal Cancer | — | 2024-12-31 |
| Not Yet Recruiting | Comparing the Efficacy of Sintilimab Plus Nab-POF Regimen, Sintilimab Plus XELOX Chemotherapy, and Lenvatinib, Gastric (Stomach) Cancer | Phase 2 | 2024-12-25 |
| Recruiting | BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC Triple-Negative Breast Cancer (TNBC), Brain Metastases | Phase 2 | 2024-12-17 |
| Recruiting | Study on the Safety and Efficacy of Intravenous Administration of IDOV-SAFETM in the Treatment of Advanced Sol Advanced Malignant Solid Tumor | EARLY_Phase 1 | 2024-12-10 |
| Recruiting | The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast Cancer Breast Cancer, Age | — | 2024-12-05 |
| Recruiting | Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clin NSCLC (Non-small Cell Lung Cancer), Artificial Intelligence (AI), Lymphnode Metastasis | — | 2024-12-01 |
| Not Yet Recruiting | First-line Treatment of Advanced/unresectable DDLPS Dedifferentiated Liposarcoma, Soft Tissue Sarcoma (STS) | Phase 2 | 2024-12-01 |
| Active Not Recruiting | A ReaL World Study of DS-8201 Breast Cancer Metastatic, Treatment Efficacy | — | 2024-12-01 |
| Recruiting | Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer Colorectal Cancer, Vitamin C, GLUT3 | Phase 3 | 2024-12-01 |
| Not Yet Recruiting | Cnidium Monnieri Detoxification Formula for Persistent High-risk Human Papillomavirus Infection of Cervix. Human Papillomavirus (HPV) Infection, Cervical Cancer | Phase 2 | 2024-12-01 |
| Not Yet Recruiting | Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer Advanced Breast Cancer, Hormone-receptor-positive Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Phase 2 | 2024-12-01 |
| Not Yet Recruiting | SHR-1701 Combined with SHR2554 and BP102 for MCRC Colorectal Cancer Metastatic | Phase 2 | 2024-12-01 |
| Not Yet Recruiting | JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer | Phase 2 | 2024-12-01 |
| Active Not Recruiting | Evaluating the Efficacy of Structured Exercise Interventions in Alleviating Aromatase Inhibitor-Induced Arthra Musculoskeletal Symptoms, Breast Cancer, Endocrine Therapy | N/A | 2024-12-01 |
| Recruiting | Multi-cohort, Single-arm Phase II Study of Albumin-paclitaxel, Ifosfamide, and Cisplatin in the Treatment of R Paget Disease, Extramammary, Rhabdomyosarcoma, Testicular Cancer | Phase 2 | 2024-11-30 |
| Not Yet Recruiting | Oral Topotecan With Toripalimab for Patients With Endometrial Cancer Endometrial Cancer | Phase 2 | 2024-11-30 |
| Recruiting | Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer Pancreatic Cancer | Phase 2 / Phase 3 | 2024-11-22 |
| Recruiting | Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer Pancreatic Cancer | Phase 2 / Phase 3 | 2024-11-22 |
| Recruiting | Ivonescimab in the Treatment of Multiple Advanced Tumors Pheochromocytoma/Paraganglioma, Rhabdomyosarcoma, Paget Disease, Extramammary | Phase 2 | 2024-11-20 |
| Not Yet Recruiting | Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophag Esophageal Squamous Cell Carcinoma | Phase 2 | 2024-11-20 |
| Recruiting | Selective Neck Dissection Versus Modified Neck Dissection in PTC Thyroid Cancer | Phase 3 | 2024-11-19 |
| Recruiting | Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-ne Breast Cancer Female, HER2-negative Breast Cancer | N/A | 2024-11-18 |
| Recruiting | A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor Treatment, Neoantigen, Vaccine | N/A | 2024-11-15 |
| Recruiting | All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic T Triple Negative Breast Cancer (TNBC) | Phase 2 | 2024-11-04 |
| Not Yet Recruiting | CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized Colon Cancer, Rectal Cancer | Phase 2 | 2024-11-01 |
| Not Yet Recruiting | CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC Colon Cancer, Rectal Cancer | Phase 2 | 2024-11-01 |
| Not Yet Recruiting | Lvosidenib (AK112) Combined With CapeOX and Radiotherapy in Patients With Unresectable Metastatic MSS-type Col CRC, MSS, Metastatic Cancer | Phase 2 | 2024-11-01 |
| Active Not Recruiting | Cola Ingestion for Esophageal Bolus Impaction Esophageal Cancer | N/A | 2024-11-01 |
| Recruiting | TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC Esophageal Carcinoma, Radiotherapy, Immunotherapy | Phase 3 | 2024-11-01 |
| Recruiting | A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppressio Ewing Sarcoma, Myelosuppression | Phase 2 | 2024-10-31 |
| Not Yet Recruiting | Vaccine Chatbot for Improving Influenza Vaccination Uptake Influenza Vaccines | N/A | 2024-10-26 |
| Recruiting | Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC) | Phase 2 | 2024-10-21 |
| Recruiting | AI-based Skeleton Recognition System for Rehabilitation Exercise in Breast Cancer Survivors: A Randomized Cont Musculoskeletal Symptoms, Breast Cancer, Endocrine Therapy | N/A | 2024-10-20 |
| Recruiting | Prevention of Recurrence and Metastasis of Colorectal Cancer by Comparing Huaier With Capecitabine Monotherapy Colorectal Cancer | Phase 4 | 2024-10-18 |
| Active Not Recruiting | Acute Effects of Low Temperature Exposure on Respiratory System Lung Function | N/A | 2024-10-16 |
| Active Not Recruiting | Acute Effects of Cold Exposure on Cognitive Function Cognitive Function | N/A | 2024-10-16 |
| Recruiting | Acute Effects of Cold Exposure on Cardiovascular System Cardiovascular System | N/A | 2024-10-16 |
| Recruiting | Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer Pancreatic Cancer | Phase 2 | 2024-10-14 |
| Recruiting | QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC TNBC, Triple Negative Breast Cancer | Phase 2 | 2024-10-09 |
| Not Yet Recruiting | The Safety and Efficacy of Multimodal Thermal Therapy in the Treatment of Early-stage Invasive Breast Cancer Breast Cancer Female | N/A | 2024-10-08 |
| Not Yet Recruiting | To Explore the Effect of Huaier Granule on the Negative Conversion Rate After the CEA Level Increases Again Af Colorectal Cancer | Phase 4 | 2024-10-01 |
| Not Yet Recruiting | EMR Versus CSP in the Treatment of Sessile Serrated Lesions Less Than 10mm in Size Colorectal Sessile Serrated Lesion | N/A | 2024-10-01 |
| Not Yet Recruiting | SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resec NMIBC | Phase 1 / Phase 2 | 2024-10-01 |
| Recruiting | AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer NSCLC (Advanced Non-small Cell Lung Cancer), Brain Metastasases | — | 2024-09-30 |
| Recruiting | Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab BRCA-Mutated Breast Carcinoma, HER2-negative Breast Cancer | Phase 2 | 2024-09-30 |
| Not Yet Recruiting | ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd Breast Cancer | Phase 2 | 2024-09-30 |
| Recruiting | Combination of TURP and Standard Systemic Therapy for MPCa Metastatic Prostate Cancer | Phase 2 | 2024-09-21 |
| Recruiting | Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy Nasopharyngeal Cancinoma (NPC) | Phase 2 | 2024-09-14 |
| Completed | RCT on the Neurobehavioral Effects of Fruits and Vegetables in Shanghai Children Cognitive Function, Mood Disorders, Attention-deficit | N/A | 2024-09-11 |
| Not Yet Recruiting | Gemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients with Locally Advance Gallbladder Cancer Unresectable | Phase 2 | 2024-09-10 |
| Active Not Recruiting | Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lympho Lymphoma, B-Cell, Marginal Zone | Phase 2 | 2024-09-10 |
| Recruiting | The Relationship of Psychological Stress With Therapy Efficacy and Prognosis of Gastric Cancer Gastric Cancer, Gastroesophageal Junction Cancer | — | 2024-09-05 |
| Active Not Recruiting | Dalpicilib-Enhanced Vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer Breast Cancer | Phase 3 | 2024-09-01 |
| Not Yet Recruiting | T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer HER2-positive Breast Cancer | Phase 2 | 2024-09-01 |
| Not Yet Recruiting | Perioperative Immunotherapy for NSCLC (ECTOP-1030) Lung Cancer | Phase 2 | 2024-09-01 |
| Not Yet Recruiting | A Single-arm, Multicenter Clinical Study of Fruquintinib Combined With Cadonilimab Injection and Temozolomide Malignant Melanoma | N/A | 2024-09-01 |
| Not Yet Recruiting | Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer Ovarian Cancer | Phase 2 | 2024-09-01 |
| Not Yet Recruiting | Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients Ovarian Cancer | Phase 2 | 2024-08-31 |
| Not Yet Recruiting | Inetetamab Combined With Paclitaxel With/Without Pertuzumab for Previously Treated HER2-positive Advanced Brea Breast Cancer Stage IV | Phase 4 | 2024-08-30 |
| Not Yet Recruiting | Precision Treatment of HR+ HER2- Advanced Breast Cancer Based on SNF Molecular Subtyping Breast Cancer | Phase 2 | 2024-08-21 |
| Recruiting | HTA of NIVATS Based on RWE Lung Cancer | — | 2024-08-20 |
| Recruiting | Effectiveness of Gut Microbiota-targeted Diatery Intervention Among Older People Living With HIV Hiv, Atherosclerosis, Diet, Healthy | N/A | 2024-08-20 |
| Not Yet Recruiting | A Clinial Trial of Lutetium [177Lu]-FAP-75 for the Treatment of Patients With Advanced Solid Tumors Solid Tumors | Phase 1 | 2024-08-19 |
| Recruiting | A Study on the Efficacy of Disitamab Vedotin in Advanced HER2-positive Paget's Disease. Mammary or Extramammary Paget's Disease | Phase 2 | 2024-08-15 |
| Recruiting | MR-guided Adaptive Radiotherapy Combined With PD-1 Antibody and CAPOX for Locally Advanced Rectal Cancer Locally Advanced Rectal Cancer | Phase 2 | 2024-08-13 |
| Recruiting | A Real World Study of Sacituzumab Govitecan Breast Cancer Metastatic, Treatment Outcome | — | 2024-08-12 |
| Recruiting | Exploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lym Relapsed/Refractory Peripheral T Cell Lymphoma | Phase 2 | 2024-08-12 |
| Recruiting | ADC-induced Neurotoxicity Treated With Duloxetine Solid Tumour | Phase 2 | 2024-08-06 |
| Not Yet Recruiting | Foot Perfusion by Dynamic Contrast Enhanced MRI in Patients With Peripheral Artery Disease Peripheral Arterial Disease, Perfusion | — | 2024-08-01 |
| Not Yet Recruiting | Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Gastric/Gastroesophageal Junction Aden Gastric Cancer, Gastro Esophageal Junction Cancer | Phase 2 | 2024-08-01 |
| Recruiting | Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer Breast Cancer | Phase 1 | 2024-07-31 |
| Not Yet Recruiting | A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy Metastatic Colorectal Cancer | Phase 2 | 2024-07-25 |
| Not Yet Recruiting | Effectiveness of Gut Microbiota-targeted Diatery Intervention Among People Living With HIV HIV, Atherosclerosis, Diet, Healthy | N/A | 2024-07-20 |
| Not Yet Recruiting | HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma Hepatocellular Carcinoma | Phase 2 | 2024-07-20 |
| Recruiting | RET Inhibitor for Neoadjuvant Therapy in Locally Advanced RET-altered Thyroid Cancer Thyroid Cancer | — | 2024-07-18 |
| Recruiting | An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Ly Diffuse Large B Cell Lymphoma | Phase 1 | 2024-07-18 |
| Recruiting | Real-world Study on the Management of Hematological Toxicities Associated With Targeted Therapies for Breast C Hematological Toxicity, Targeted Therapy, Breast Cancer | — | 2024-07-15 |
| Recruiting | Adjuvant Radiotherapy in High Risk Locally Advanced DTC Thyroid Cancer | Phase 3 | 2024-07-11 |
| Recruiting | LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Br TNBC - Triple-Negative Breast Cancer | Phase 2 | 2024-07-10 |
| Recruiting | AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy Head and Neck Squamous Cell Carcinoma | Phase 2 | 2024-07-03 |
| Recruiting | RW Study of Adjuvant Radiotherapy in Locally Advanced Thyroid Cancer Thyroid Cancer | — | 2024-07-02 |
| Recruiting | Segmentectomy for Solid-dominant Lung Cancer Segmentectomy, Lung Adenocarcinoma | Phase 3 | 2024-07-01 |
| Not Yet Recruiting | Enhanced vs. Routine Follow-Up After Total Gastrectomy for Advanced Gastric Cancer: A Randomized Controlled Tr Gastric Cancer, Total Gastrectomy, Postoperative Care | N/A | 2024-07-01 |
| Not Yet Recruiting | Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma，Bispecific Antibodies, HAIC, Ramucirumab | Phase 2 | 2024-07-01 |
| Recruiting | Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Stable Brain Met NSCLC Stage IV, Brain Metastases | Phase 2 | 2024-07-01 |
| Active Not Recruiting | Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage II NSCLC, Locally Advanced Lung Carcinoma | Phase 2 | 2024-07-01 |
| Suspended | Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric Adenocarcinoma Stomach Adenocarcinoma, Gastro-esophageal Junction Cancer | Phase 2 | 2024-07-01 |
| Recruiting | Cranial Radiotherapy Plus Chemoimmunotherapy in Untreated Driver-mutation Negative NSCLC With Active Brain Met NSCLC Stage IV | Phase 2 | 2024-07-01 |
| Recruiting | A Prospective Cohort Study on the Serum Kisspeptin Levels Throughout Pregnancy in PCOS Polycystic Ovary Syndrome, Pregnancy Complications | — | 2024-06-28 |
| Recruiting | Multi-omics Model for Pancreatic Cancer Screening Using cfDNA Pancreatic Cancer | — | 2024-06-28 |
| Recruiting | Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | 2024-06-26 |
| Recruiting | First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients Pancreatic Cancer | Phase 2 | 2024-06-20 |
| Completed | Financial Navigation Program for Improving Financial Toxicity Among Breast Cancer in China Breast Neoplasm Female, Financial Toxicity, Financial Navigation | N/A | 2024-06-17 |
| Recruiting | Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer Pancreatic Cancer | Phase 2 | 2024-06-05 |
| Recruiting | Combination of Toripalimab and JS004 Therapy for ccRCC Clear Cell Renal Cell Carcinoma | Phase 2 | 2024-06-01 |
| Recruiting | PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients Pancreatic Cancer | Phase 2 | 2024-06-01 |
| Recruiting | A Cohort Study in Newly Diagnosed MZL Marginal Zone Lymphoma | — | 2024-05-30 |
| Recruiting | Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer Pancreatic Cancer | Phase 1 / Phase 2 | 2024-05-29 |
| Recruiting | A Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lympho Mantle Cell Lymphoma, Maintenance Therapy | Phase 2 | 2024-05-24 |
| Completed | Efficacy and Safety of Interferon-Gamma Monoclonal Antibody Combined With Dexamethasone in the Treatment of Re Adult Refractory Secondary Hemophagocytic Lymphohistiocytosis, Secondary Hemophagocytic Lymphohistiocytosis, HLH | — | 2024-05-21 |
| Not Yet Recruiting | Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Chola Intrahepatic Cholangiocarcinoma | N/A | 2024-05-20 |
| Recruiting | Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer Triple-negative Breast Cancer | Phase 2 | 2024-05-20 |
| Recruiting | Radiotherapy to Patients With CA19-9-elevated Advanced Pancreatic Cancer Pancreatic Adenocarcinoma | Phase 3 | 2024-05-15 |
| Not Yet Recruiting | The Impact of Colorectal Cancer Screening on Surgical Outcomes Prognosis, Colorectal Cancer, Screening | — | 2024-05-11 |
| Completed | Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer Triple-negative Breast Cancer | Phase 2 | 2024-05-11 |
| Recruiting | Short-course Radiotherapy Combined With CapeOx and PD-1 Inhibitor After Local Excision for High-risk Early Rec Rectal Cancer | Phase 2 | 2024-05-08 |
| Not Yet Recruiting | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer Early Breast Cancer, Neoadjuvant Therapy, TNBC, Triple Negative Breast Cancer | Phase 2 | 2024-05-07 |
| Not Yet Recruiting | QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer Early Breast Cancer, Neoadjuvant Therapy, HR+HER2- Breast Cancer | Phase 2 | 2024-05-06 |
| Recruiting | Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Cadonil Gastric / Gastroesophageal Junction Adenocarcinoma | Phase 2 | 2024-05-01 |
| Not Yet Recruiting | Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer Colorectal Cancer | Phase 2 | 2024-05-01 |
| Recruiting | Selective Lymph Node Resection for Invasive Non-small Cell Lung Cancer With the CTR of 0.5-1 and the Diameter Lung Cancer (NSCLC), Lymph Node Dissection | N/A | 2024-05-01 |
| Completed | NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy | Phase 3 | 2024-05-01 |
| Not Yet Recruiting | Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE RECTAL NEOPLASMS, Rectal Cancer | Phase 2 | 2024-05-01 |
| Recruiting | Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients 3-year Disease-free Survival | Phase 4 | 2024-05-01 |
| Not Yet Recruiting | Newly Emerging Immunotherapy for Pancreatic Cancer Treatment Pancreatic Cancer | Phase 1 / Phase 2 | 2024-04-30 |
| Not Yet Recruiting | Impact of a Mock-up Fact-checking Extension on HPV Vaccine Misinformation: A Survey Experiment HPV Vaccine | N/A | 2024-04-28 |
| Completed | The Antagonistic Effect of Composite Polyphenols on Health Damage Caused by Environmental Pollutants Intestinal Functional Disorder, Inflammation | N/A | 2024-04-23 |
| Recruiting | A Study of the Intervention of Time-restricted Eating in High-risk Populations of GDM Gestational Diabetes Mellitus, Dietary Habits, Lifestyle Intervention | N/A | 2024-04-17 |
| Recruiting | Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC Small Cell Lung Cancer Recurrent | N/A | 2024-04-17 |
| Recruiting | A Clinical Research About CD70-targeted CAR-NKT Cells Therapy Advanced Malignant Solid Tumors Solid Tumor | Phase 1 | 2024-04-11 |
| Recruiting | Lymph Node Pathologic Grading Strategy Lung Adenocarcinoma | — | 2024-04-10 |
| Recruiting | Treatment Response Adapted Hybrid Radiotherapy in Metastatic Non-small Cell Lung Cancer Receiving First-line I NSCLC Stage IV | Phase 2 | 2024-04-10 |
| Recruiting | Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3) Thymic Carcinoma | Phase 3 | 2024-04-09 |
| Recruiting | Chemotherapy Omission in ER+/HER2- Breast Cancer With 1-3 Positive Lymph Nodes Receiving Extended Adjuvant Abe Breast Cancer | Phase 3 | 2024-04-02 |
| Recruiting | Primary Tumor Resection for M1a Stage Lung Cancer Lung Cancer Metastatic, Surgical Resection | — | 2024-04-01 |
| Not Yet Recruiting | Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients Colon Cancer | Phase 2 | 2024-04-01 |
| Recruiting | Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Microsatellite Stable Metastatic Colorectal Cancer | Phase 2 | 2024-04-01 |
| Recruiting | Short-course Radiotherapy Combined With CAPOX and PD-1 Antibody Versus Long-course Chemoradiotherapy Combined Early Low Rectal Cancer | Phase 2 | 2024-04-01 |
| Recruiting | Effect of Butyphthalide on Cognitive Level Change After Cerebral Vascular Event-a Randomized Control Trial (Be Stroke, Post-stroke Cognitive Impairment (PSCI) | Phase 3 | 2024-04-01 |
| Completed | Non-Dressing vs. Routine Dressing Change After Gastrointestinal Cancer Surgery Gastrointestinal Tumors, Surgical Wound Infection, Pain, Postoperative | N/A | 2024-04-01 |
| Not Yet Recruiting | Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (E Lung Cancer, EGFR Gene Mutation, Minimal Residual Disease | Phase 3 | 2024-04-01 |
| Recruiting | mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemothe Pancreatic Cancer, Radiotherapy | Phase 2 | 2024-04-01 |
| Recruiting | CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer Locally Advanced Rectal Cancer, Neoadjuvant Therapy | Phase 2 | 2024-03-28 |
| Recruiting | The Efficacy of PD-1 Monoclonal Antibody Combined With Chemotherapy in Metastatic Gastric Cancer Based on Gut Gastric Cancer, Gut Microbiota | — | 2024-03-14 |
| Recruiting | clinIcal Efficacy and Safety of Incadronate in Breast Cancer With Bone Metastases Breast Cancer, Bone Metastases | — | 2024-03-12 |
| Recruiting | Metronomic Capecitabine in Stage III Gastric Cancer Gastric Cancer | Phase 3 | 2024-03-10 |
| Recruiting | Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | Phase 2 | 2024-03-04 |
| Recruiting | Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherap Microsatellite Stable Metastatic Colorectal Cancer | Phase 2 | 2024-03-01 |
| Recruiting | Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma MALT Lymphoma of Stomach, Helicobacter Pylori Infection | Phase 2 | 2024-03-01 |
| Recruiting | Comparing 68Ga-FAPI PET-Guided Abdominal Radiotherapy Combined With Second-Line Standard Therapy and Cadonilim Colorectal Cancer, Peritoneal (Metastatic) Cancer, FAPI PET | Phase 2 | 2024-03-01 |
| Recruiting | Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer Pancreatic Cancer | Phase 2 | 2024-03-01 |
| Unknown | Effectiveness of Gut Microbiota-targeted Dietary Intervention Among HIV-infected Patients Hiv, Cardiovascular Diseases, Diet, Healthy | N/A | 2024-03-01 |
| Recruiting | Real-world Effectiveness and Safety Study of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer Breast Cancer | — | 2024-03-01 |
| Recruiting | Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clin Large B-Cell Lymphoma | — | 2024-02-29 |
| Completed | Pilot Study of Financial Navigation Program for Improving Financial Toxicity Among Breast Cancer in China Breast Neoplasm Female, Financial Toxicity, Financial Navigation | N/A | 2024-02-18 |
| Not Yet Recruiting | HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cance Pancreatic Cancer | Phase 3 | 2024-02-05 |
| Recruiting | Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer Advanced Breast Cancer, HR+/HER2- Breast Cancer | Phase 3 | 2024-02-01 |
| Not Yet Recruiting | SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases TNBC, Brain Metastasis | Phase 2 | 2024-02-01 |
| Unknown | Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID) Prostate Cancer Metastatic, Castration-resistant Prostate Cancer | Phase 2 | 2024-01-30 |
| Recruiting | Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer Breast Cancer, Sentinel Lymph Node, Frozen Section | N/A | 2024-01-30 |
| Recruiting | Effectiveness of Vaccine Chatbot on HPV Vaccine Awareness and Vaccination in China HPV Vaccine | N/A | 2024-01-18 |
| Recruiting | Proteomic Guided First-line Precision Treatment of Renal Clear Cell Carcinoma Kidney Cancer, Renal Cell Carcinoma, Renal Clear Cell Carcinoma | Phase 2 | 2024-01-16 |
| Recruiting | WBRT With Hippocampal-avoidance Technique Followed by SRT for Extensive-stage SCLC With Baseline Brain Metasta SCLC,Extensive Stage, Brain Metastases | Phase 1 / Phase 2 | 2024-01-15 |
| Recruiting | mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Pancreatic Adenocarcinoma | Phase 2 | 2024-01-10 |
| Recruiting | Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metast HER2-negative Breast Cancer, Leptomeningeal Metastasis | Phase 4 | 2024-01-05 |
| Unknown | A Study on the Prognosis of Two Different Surgery Methods in Patients With Rectal Endometriosis Gastrointestinal Function, Quality of Life, Pregnancy Outcomes | — | 2024-01-01 |
| Recruiting | Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unrese Metastatic Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma, RAS Mutation | Phase 2 | 2024-01-01 |
| Not Yet Recruiting | Comparison of Kimura Versus Warshaw Technique for Laparoscopic Spleen-Preserving Distal Pancreatectomy Pancreatic Tumor, Benign, Pancreatic Neuroendocrine Tumor, Solid Pseudopapillary Tumor of the Pancreas | N/A | 2024-01-01 |
| Unknown | DEBIRI Combined With Chemotherapy and Bevacizumab in the Treatment of Unresectable Colorectal Cancer Liver Met Colorectal Neoplasms | N/A | 2024-01-01 |
| Recruiting | Predicting Tumor Metastasis by Employing a Target Organ/Primary Lesion Fusion Radiomics Model Metastasis, Predictive Cancer Model | — | 2024-01-01 |
| Not Yet Recruiting | Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Aden Pancreatic Cancer | EARLY_Phase 1 | 2024-01-01 |
| Recruiting | Exploration of Therapeutic Strategies for NeoRAS Wild-type Metastatic Colorectal Cancer Based on Circulating T Colorectal Cancer Metastatic | Phase 2 | 2023-12-28 |
| Recruiting | A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection Pancreatic Cancer | — | 2023-12-18 |
| Recruiting | Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer Non-muscle Invasive Bladder Cancer, HER-2 Protein Overexpression | Phase 2 | 2023-12-18 |
| Recruiting | Liquid Biopsy-based Early Detection of Ovarian Cancer: a Proof-of-concept Study ( PROFOUND-OC ) Ovarian Cancer | — | 2023-12-18 |
| Not Yet Recruiting | A Perioperative Sintilimab and Chemotherapy in Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma | Phase 2 | 2023-12-15 |
| Recruiting | A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatme Pancreatic Cancer Metastatic | Phase 2 | 2023-12-05 |
| Recruiting | TPF Concurrent Chemo-radiotherapy Plus Immunotherapy for Local Advanced Esophageal Squamous Cell Carcinoma Esophageal Squamous Cell Carcinoma | N/A | 2023-12-01 |
| Recruiting | Cisplatin to Patients With Pancreatic Cancer and Homologous Recombination Deficiency Pancreatic Adenocarcinoma, Homologous Recombination Deficiency | Phase 2 / Phase 3 | 2023-12-01 |
| Recruiting | Tislelizumab Plus GX Versus Tislelizumab Plus GP in the Treatment of R/M NPC Nasopharyngeal Carcinoma | Phase 3 | 2023-12-01 |
| Recruiting | Adjuvant Treatment for Incomplete Resection Thymoma or Thymic Carcinoma Thymoma and Thymic Carcinoma | Phase 3 | 2023-12-01 |
| Completed | Heterogeneity of Tertiary Lymphoid Structures Predicts Distinct Malignancy and Immune Microenvironment in Pros Prostate Cancer | — | 2023-12-01 |
| Unknown | Assessment of Early Pancreatic Cancer Prognosis by Minimal Residual Disease Using Multi-omics Approach Pancreatic Ductal Adenocarcinoma | — | 2023-12-01 |
| Unknown | Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Adva Hepatocellular Carcinoma | Phase 2 | 2023-12-01 |
| Unknown | Thoracic Consolidation Radiotherapy for ES-SCLC Treated With Chemo-immunotherapy Small Cell Lung Cancer Extensive Stage | Phase 1 | 2023-12-01 |
| Unknown | A Study of Surufatinib in the Treatment of Advanced Soft Tissue Sarcoma Soft Tissue Sarcoma Adult | N/A | 2023-11-28 |
| Completed | Effect of ESPB on Postoperative Pain in Patients With Breast Cancer Implant Reconstruction Mammary Cancer, Erector Spinae Plane Block, Postoperative Pain | N/A | 2023-11-20 |
| Recruiting | A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negativ Gastric Cancer/Adenocarcinoma of Esophagogastric Junction | N/A | 2023-11-20 |
| Recruiting | Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer Pancreatic Cancer Stage IV, Chemotherapy-induced Nausea and Vomiting | Phase 3 | 2023-11-01 |
| Recruiting | Surveillance for Multifocal GGNs Lung Ground-glass Opacities, Active Surveillance | — | 2023-11-01 |
| Active Not Recruiting | PET-CT Predicting Lymph Nodes Metastasis Non Small Cell Lung Cancer, Lymph Node Metastasis, Positron Emission Tomography | — | 2023-11-01 |
| Not Yet Recruiting | Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020) Lung Cancer, Wedge Resection, Ground-glass Opacity | Phase 3 | 2023-11-01 |
| Not Yet Recruiting | A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases Breast Cancer, Brain Metastases, Radiotherapy | Phase 2 | 2023-11-01 |
| Unknown | Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC Colorectal Cancer | Phase 2 | 2023-10-31 |
| Unknown | Real World Patient-Reported Outcomes in Chinese Her2+ EBC Patients Receiving (Neo) Adjuvant Anti-Her2 Based Th HER2-positive Breast Cancer | — | 2023-10-26 |
| Unknown | Comparison of the Sugarbaker and Keyhole Repair for Parastomal Hernia Parastomal Hernia | — | 2023-10-20 |
| Recruiting | Cohort of Twin Pregnancy and the Offspring Twin Pregnancy | — | 2023-10-15 |
| Unknown | Acute Health Effects of Low Temperature Exposure Cardiovascular System, Respiratory System, Cognitive Function | N/A | 2023-10-10 |
| Recruiting | A Prospective Multicentre Clinical Study of Dynamic Monitoring of Plasma ctDNA Methylation Markers to Predict Colorectal Cancer, Peritoneal Metastases | — | 2023-10-01 |
| Recruiting | LRAMPS Versus LDP in Selected Early-stage Left-sided Pancreatic Cancer Left-sided Pancreatic Cancer | N/A | 2023-10-01 |
| Not Yet Recruiting | Tongxinluo Capsule in the Treatment of Cerebral Small Vessel Disease-A Randomized, Double-blind, Placebo-contr Cerebral Small Vessel Diseases | Phase 4 | 2023-10-01 |
| Not Yet Recruiting | Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis Breast Cancer Stage IV | Phase 4 | 2023-10-01 |
| Unknown | Suture Repair vs Mesh Repair in the Treatment of Incarcerated Groin Hernia in Elderly Populations Incarcerated Groin Hernia | — | 2023-09-30 |
| Unknown | Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With Hi Radiotherapy, Immunotherapy, Liver Metastases | Phase 2 | 2023-09-25 |
| Recruiting | Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients Bladder Cancer | Phase 1 | 2023-09-21 |
| Unknown | Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal M Advanced Mucosal Melanoma | Phase 2 | 2023-09-18 |
| Recruiting | Cryoablation Combined with Tislelizumab Plus Lenvatinib in Previously Treated Solid Tumors (CASTLE-11) Solid Tumor, Adult | Phase 2 | 2023-09-13 |
| Recruiting | Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Lu Triple Negative Breast Cancer, Metastatic Breast Cancer, Mutation | Phase 3 | 2023-09-13 |
| Recruiting | Multicenter Clinical Translational Study of "ICU-NO CRBSI" Based on Improvement Science CRBSI - Catheter Related Bloodstream Infection, Evidence-based Nursing Practice, Central Venous Catheter Related Bloodstream Infection | N/A | 2023-09-04 |
| Unknown | The Application of Probe Confocal Laser Endomicroscopy in Pancreatic Tumor Surgery Pancreatic Cancer, Diagnosis, Pancreatoduodenectomy | N/A | 2023-09-01 |
| Completed | Positive ER Expression Assessed by 18F-FES PET/CT in the MBC with ER-negative Primary Tumor Breast Cancer | — | 2023-09-01 |
| Not Yet Recruiting | Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Colorectal Cancer, Liver Metastases | — | 2023-09-01 |
| Recruiting | Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer Metastatic Pancreatic Cancer, Terminal Cancer | Phase 2 | 2023-08-25 |
| Recruiting | Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Larynx Cancer, Hypopharyngeal Cancer | Phase 2 | 2023-08-22 |
| Active Not Recruiting | Vitamin C to Chemotherapy Related Anemia in Pancreatic Cancer Metastatic Pancreatic Adenocarcinoma | Phase 3 | 2023-08-20 |
| Recruiting | A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in P TNBC - Triple-Negative Breast Cancer | Phase 3 | 2023-08-20 |
| Active Not Recruiting | SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI Brain Metastases, Non-small Cell Lung Cancer | Phase 2 | 2023-08-10 |
| Recruiting | Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer Differentiated Thyroid Cancer | Phase 2 | 2023-08-04 |
| Not Yet Recruiting | T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients Triple-Negative Breast Cancer | Phase 2 | 2023-08-01 |
| Recruiting | Novel Therapy Target in Metastatic Prostate Cancer Prostate Neoplasms | — | 2023-08-01 |
| Unknown | Circulating Tumor DNA Monitoring in Platinum-resistant Ovarian Cancer Ovarian Cancer | — | 2023-08-01 |
| Recruiting | Circulating Tumor DNA Methylation Guided Postoperative Adjuvant Chemotherapy for High-risk Stage II/III Colore High-risk Stage II Colorectal Cancer, Stage III Colorectal Cancer, Circulating Tumor DNA Methylation | Phase 3 | 2023-08-01 |
| Active Not Recruiting | A Phase II Study of Advanced Salivary Gland Carcinoma Based on Molecular Typing Advanced Salivary Gland Carcinoma | Phase 2 | 2023-07-26 |
| Recruiting | Efficacy of Everolimus Combined With First-line Endocrine Therapy for HR+/HER2- SNF1-subtype Advanced Breast C Breast Cancer, Advanced Breast Cancer | Phase 2 | 2023-07-26 |
| Recruiting | DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Mul Renal Insufficiency, Upper Urinary Tract Urothelial Carcinoma, Solitary Kidney | Phase 2 | 2023-07-20 |
| Recruiting | A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in Advanced Non-liver-li Colorectal Cancer | Phase 2 | 2023-07-20 |
| Unknown | CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma Renal Cell Carcinoma | Phase 1 | 2023-07-17 |
| Completed | 18F-fluoroestradiol (18F-FES) PET/CT Guided First-line Treatment for HR+/HER2- Metastatic Breast Cancer Patien Breast Cancer | — | 2023-07-15 |
| Not Yet Recruiting | Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM Colorectal Cancer, Liver Metastases | Phase 3 | 2023-07-15 |
| Active Not Recruiting | Liposomal Irinotecan Based FOLFIRI With Bevacizumab in First-line Treatment of Advanced Colorectal Cancer Colorectal Cancer | Phase 2 | 2023-07-10 |
| Unknown | The Clinical Value of an Artificial Intelligence System Using Abbreviated Protocol of Breast MRI Facilitates C Breast Cancer | — | 2023-07-01 |
| Not Yet Recruiting | Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-s Colorectal Carcinoma, Liver Metastases | N/A | 2023-07-01 |
| Recruiting | Regorafenib Combined With TAS-102 Versus Regorafenib Monotherapy in Third or Later Line Therapy of mCRC Metastatic Colorectal Cancer | Phase 2 | 2023-07-01 |
| Unknown | An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE TNBC - Triple-Negative Breast Cancer | Phase 1 / Phase 2 | 2023-07-01 |
| Unknown | A Study of HRXG-K-1939 and Adebrelimab in Patients With Advanced Solid Tumors Advanced Solid Tumors | Phase 1 | 2023-07-01 |
| Not Yet Recruiting | Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC Advanced Non-Small Cell Lung Cancer | Phase 2 | 2023-07-01 |
| Recruiting | Postoperative Effects of Different Enterostomy Approaches Colorectal Cancer, Colorectal Neoplasms Malignant, Intestinal Neoplasms, Malignant | N/A | 2023-06-23 |
| Unknown | Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10) Hepatocellular Carcinoma | Phase 2 | 2023-06-20 |
| Recruiting | Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Breast Cancer, Triple Negative Breast Cancer | Phase 3 | 2023-06-20 |
| Unknown | The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Ca Metastatic Colorectal Cancer | Phase 2 | 2023-06-18 |
| Unknown | Axillary Surgery De-escalation After Neoadjuvant Therapy Using Dedicate Breast PET Breast Cancer | N/A | 2023-06-18 |
| Unknown | Cryoablation Combined With Tislelizumab Plus Lenvatinib In Previously Treated Gastric Cancer Liver Metastasis Gastric Cancer Metastatic to Liver | Phase 2 | 2023-06-16 |
| Recruiting | Circulating Tumor DNA Methylation Guided Postoperative Follow-up Strategy for Non-metastatic Colorectal Cancer Non-metastatic Colorectal Cancer, Circulating Tumor DNA Methylation | N/A | 2023-06-15 |
| Recruiting | EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer HER2 Positive Early Breast Cancer | Phase 3 | 2023-06-07 |
| Recruiting | Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer Breast Cancer Stage I | Phase 2 | 2023-06-01 |
| Recruiting | A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Th TNBC - Triple-Negative Breast Cancer | Phase 3 | 2023-06-01 |
| Recruiting | TCb vs EC-T in High Risk ER+/HER2- Breast Cancer Hormone Receptor Positive HER-2 Negative Breast Cancer | Phase 3 | 2023-06-01 |
| Recruiting | Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Br Breast Cancer | Phase 3 | 2023-06-01 |
| Not Yet Recruiting | A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Bre HR+/HER2-breast Cancer | Phase 3 | 2023-06-01 |
| Unknown | Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis Patient Colorectal Cancer Liver Metastases | N/A | 2023-06-01 |
| Completed | A Home Telemonitoring System for Wearable Fetal-ECG and EHG Acquisition During Pregnancy Uterine Contractions; Prolonged, Fetal Heart Rate or Rhythm Abnormality Affecting Fetus, Pregnancy Related | — | 2023-05-29 |
| Active Not Recruiting | Abemaciclib, Palbociclib or Dalpiciclib Combined with Endocrine Therapy As First-line Treatment in HR Positive Breast Cancer | — | 2023-05-20 |
| Completed | Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unr Breast Cancer | — | 2023-05-20 |
| Unknown | Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cance Advanced Biliary Tract Cancer | Phase 2 | 2023-05-16 |
| Recruiting | HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC Intrahepatic Cholangiocarcinoma | Phase 2 | 2023-05-11 |
| Unknown | Disitamab Vedotin, Fruquintinib and Tislelizumab in Second-line Treatment for HER2-positive MGC HER2-positive Gastric Cancer, Immunotherapy | Phase 1 / Phase 2 | 2023-05-09 |
| Not Yet Recruiting | Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer Breast Cancer | Phase 3 | 2023-05-06 |
| Completed | Transcutaneous Electrical Nerve Stimulation in Nerve-Sparing Radical Hysterectomy: Effects on Bladder Manageme Cervical Cancer, Postoperative Bladder Dysfunction, Urinary Retention | N/A | 2023-05-02 |
| Not Yet Recruiting | Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Tre Metastatic Prostate Cancer, Castration-Sensitive Prostate Cancer | Phase 2 | 2023-05-01 |
| Unknown | Long-term Prognosis for Non-functional Neuroendocrine Tumors of the Pancreatic Body and Tail ≤ 3cm Non Functioning Pancreatic Endocrine Tumor | — | 2023-05-01 |
| Unknown | Combination of Chidamide and Fulvestrant for HR+/HER2- Breast Cancer That Has Failed Previous CDK4/6 i Adjuvan Hormone Receptor-positive Advanced Breast Cancer | Phase 2 | 2023-05-01 |
| Unknown | Clinical Efficacy of QYHJ and Standard Chemotherapy in the Treatment of Advanced Pancreatic Cancer Pancreatic Neoplasms | Phase 3 | 2023-05-01 |
| Unknown | The Efficacy and Safety of The Fuzuloparib Combination With Bevacizumab Recurrent Ovarian Cancer | Phase 2 | 2023-04-30 |
| Unknown | Cryoablation Combined With Sintilimab Plus Lenvatinib in 1L Treatment of Advanced ICC (CASTLE-ICC-Chemo-free) Advanced Intrahepatic Cholangiocarcinoma | Phase 2 | 2023-04-28 |
| Unknown | A Cohort Study of Musculoskeletal Health in Patients With Breast Cancer During Aromatase Inhibitors Therapy Musculoskeletal Health | — | 2023-04-27 |
| Recruiting | Precise Treatment for BLIS Subtype of TNBC in the First-line Treatment of Locally Advanced or Metastatic Breas Triple-Negative Breast Cancer | Phase 3 | 2023-04-25 |
| Recruiting | Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastati Microsatellite Stable Metastatic Colorectal Cancer | Phase 2 | 2023-04-25 |
| Recruiting | Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1 Lung Adenocarcinoma, Lymph Node Metastasis | Phase 3 | 2023-04-01 |
| Unknown | Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver Metastases Nasopharyngeal Carcinoma, Liver Metastases | N/A | 2023-04-01 |
| Recruiting | Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Fr Lung Adenocarcinoma, Frozen Section, Sublobar Resection | Phase 3 | 2023-03-31 |
| Recruiting | FUSCC Refractory TNBC Platform Study (FUTURE2.0) Triple-negative Breast Cancer | Phase 2 | 2023-03-30 |
| Unknown | Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Immune Checkpoint Inhibitor Previously Advanced Biliary Tract Cancer | Phase 2 | 2023-03-23 |
| Completed | Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients Squamous Cell Carcinoma of Head and Neck | Phase 2 | 2023-03-22 |
| Recruiting | Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Adv Triple-Negative Breast Cancer | Phase 3 | 2023-03-17 |
| Completed | Evaluate the Efficacy and Safety of Serplulimab Plus Chemotherapy in Neoadjuvant and Adjuvant Treatment of Res Non-small Cell Lung Cancer, Stage II-IIIA, Immunotherapy | Phase 2 | 2023-03-15 |
| Active Not Recruiting | Different Targeted Antibody-drug Conjugates For HER2 Ultra-low or No Expression Advanced Breast Cancer（GALAXY） Breast Cancer | Phase 1 / Phase 2 | 2023-03-14 |
| Unknown | A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Com Triple-Negative Breast Cancer | Phase 2 | 2023-03-01 |
| Completed | A Retrospective Analysis of Incisional Hernia Repair's Postoperative Recurrence Incisional Hernia, Recurrent Hernia | — | 2023-03-01 |
| Unknown | Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma Ovarian Clear Cell Carcinoma | Phase 1 / Phase 2 | 2023-03-01 |
| Unknown | Application of "Heidelberg Triangle" Dissection in Pancreatoduodenectomy and Distal Pancreatectomy Pancreatoduodenectomy, Periampullary Carcinoma, Pancreatic Cancer | — | 2023-03-01 |
| Unknown | Oncolytic Virotherapy Plus PD-1 Inhibitor and Lenvatinib as Second-line or Later Therapy in Patients With Adva Hepatocellular Carcinoma | Phase 1 | 2023-03-01 |
| Recruiting | Vitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cance Colorectal Cancer, Microsatellite Stable Colorectal Carcinoma | Phase 2 | 2023-03-01 |
| Unknown | The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Rec Homologous Recombination Deficiency Alterations Metastatic Colorectal Cancer | Phase 2 | 2023-03-01 |
| Completed | Pulmonary Ventilation Function Between Patients With Primary and Recurrent Incisional Hernia: a Cross-sectiona Incisional Hernia, Recurrent Hernia, COPD | — | 2023-03-01 |
| Completed | Transcriptomic Analysis of Incisional Hernia Based on High-throughput Sequencing Technology Incisional Hernia, Extracellular Matrix Alteration | — | 2023-03-01 |
| Unknown | Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORC Locally Advanced Colon Cancer | Phase 2 | 2023-03-01 |
| Recruiting | A Study of IO Plus Radiotherapy in Patients With Advanced ESCC. Metastatic Esophageal Squamous Cell Carcinoma | N/A | 2023-02-28 |
| Recruiting | Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors Pancreatic Neuroendocrine Tumor, Solid Pancreatic Neoplasms | — | 2023-02-27 |
| Unknown | PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale Cancers, PERCEIVE-II Gynecologic Cancer | — | 2023-02-22 |
| Recruiting | Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative T Esophageal Squamous Cell Carcinoma | Phase 2 | 2023-02-20 |
| Recruiting | Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012) Segmentectomy, Lung Adenocarcinoma | Phase 3 | 2023-02-15 |
| Unknown | Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer Gastric Cancer, Chemotherapy Effect, Immune Checkpoint Inhibitor | Phase 2 | 2023-02-09 |
| Recruiting | Apatinib With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2- Advanced Breast Cancer Breast Cancer Metastatic | Phase 2 | 2023-02-01 |
| Recruiting | PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer Breast Cancer Metastatic | Phase 2 | 2023-02-01 |
| Unknown | a Study of Combined mpMRI and PSMA PET/CT for Highly Suspicious Patients Performing Radical Prostatectomy With Prostatic Neoplasms, Prostatectomy, Prostate Biopsy | — | 2023-01-10 |
| Unknown | Different Immunochemotherapies in Small B-cell Non-Hodgkin Lymphoma (iNHL) Lymphoma, Non-Hodgkin | — | 2023-01-10 |